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Abstract
Objective: Hypospadias is a frequent congenital anomaly but in most cases an underlying cause is not
found. Steroidogenic factor 1 (SF-1, NR5A1, Ad4BP) is a key regulator of human sex development and
an increasing number of SF-1 (NR5A1) mutations are reported in 46,XYdisorders of sex development
(DSD). We hypothesized that NR5A1 mutations could be identiﬁed in boys with hypospadias.
Design and methods: Mutational analysis of NR5A1 in 60 individuals with varying degrees of
hypospadias from the German DSD network.
Results: Heterozygous NR5A1 mutations were found in three out of 60 cases. These three individuals
represented the most severe end of the spectrum studied as they presented with penoscrotal
hypospadias, variable androgenization of the phallus and undescended testes (three out of 20 cases
(15%) with this phenotype). Testosterone was low in all three patients and inhibin B/anti-Mu ¨llerian
hormone (AMH) were low in two patients. Two patients had a clear male gender assignment. Gender
re-assignment to male occurred in the third case. Two patients harbored heterozygous nonsense
mutations (p.Q107X/WT, p.E11X/WT). One patient had a heterozygous splice site mutation in intron
2 (c.103-3A/WT) predicted to disrupt the main DNA-binding motif.Functional studies of the nonsense
mutants showed impaired transcriptional activation of an SF-1-responsive promoter (Cyp11a). To date,
adrenal insufﬁciency has not occurred in any of the patients.
Conclusions: SF-1 (NR5A1) mutations should be considered in 46,XY individuals with severe
(penoscrotal) hypospadias, especially if undescended testes, low testosterone, or low inhibin B/AMH
levels are present. SF-1 mutations in milder forms of idiopathic hypospadias are unlikely to be
common.
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Introduction
Hypospadias is one of the most frequent congenital
anomalies in boys, occurring with a frequency of
approximately one in every 250 newborn males (1, 2).
The clinical spectrum of this condition ranges from
severe forms, where the urethra opens in the scrotum
or penoscrotal junction, to milder forms, where the
urethral opening is located on the penile midshaft
or glans. Some cases of hypospadias are associated
with speciﬁc syndromic features and, in some cases,
underdevelopment of the phallus and/or undescended
testes may be present.
Hypospadias results from aventral fusion defect of the
urethra during embryonic development, which occurs
between 8 and 12 weeks gestation in humans (3). The
ﬁrst phase of elongation and patterning of the genital
tubercle occurs in both sexes and is mainlycontrolled by
developmental genes (e.g. SHH, HOXA13, HOXD13)
and local growth factors (e.g. FGF8, FGF10, FGFR-IIIB,
BMP7). The second phase of phallic growth occurs in
males under the inﬂuence of androgen (dihydrotestos-
terone, DHT) action (4). In rare cases, a defect in one of
these factors has been found to be associated with
syndromic or nonsyndromic forms of hypospadias in
humans (e.g. HOXA13, FGF8, FGFR2) (5, 6). Similarly,
variable loss-of-function changes in the transcription
factors, receptors, and enzyme pathways involved in
Leydig cell development, androgen biosynthesis, and
androgen action have also been found to be a cause of
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STAR, CYP11A1, HSD3B2, CYP17A1, POR, HSD17B3,
SRD5A2, AR) (7–12). These patients often have
associated micropenis and unilateral or bilateral
cryptorchidism as androgens are implicated in phallic
growth and the second stage of testis descent.
Furthermore, mutations in the Wilms’ tumor suppres-
sor gene (WT1), a gene that plays a role in testis and
kidney development, have been described in patients
with hypospadias and kidney disease (13, 14).
Despite advances in our understanding of these
developmental processes, the exact etiology of hypospa-
dias remains unknown in most cases. It is quite possible
that multifactorial inﬂuences are important, and
environmental modulators of the androgen/estrogen
pathway (e.g. pesticides) have been implicated in the
potential population increase in this condition (15).
However, it is plausible that other single gene disorders
may result in hypospadias, either alone or as part of an
oligogenicnetwork.Onekeycandidategeneknowntobe
involved in testis development and steroidogenesis is
NR5A1, which encodes the nuclear receptor steroido-
genic factor 1 (SF-1, Ad4BP) (16). Mutations in NR5A1
areemergingasarelativelyfrequentcauseofsomeforms
of 46,XY disorders of sex development (DSD; partial
testicular dysgenesis, impaired androgen synthesis) and
in most cases reported to date, the underandrogeniza-
tion has been sufﬁciently severe to lead to a female
gender assignment (17–19). Here, we investigate the
frequencyofNR5A1mutationsinacohortofindividuals
with severe penile or penoscrotal hypospadias.
Methods
Patients
The cohort studied consisted of 60 46,XY DSD patients
from the ‘German Network of Disorders of Sex Develop-
ment’ who had presented at birth with variable degrees
ofhypospadiasrangingfromseverepeniletopenoscrotal
forms. Twenty-four patients had penile hypospadias. Of
these, 18 patients had descended testes and six patients
had at least one undescended testis. Thirty-six patients
had peno-scrotal hypospadias. Of these, 16 patients had
descended testes and 20 patients had at least one
undescended testis. Adrenal insufﬁciency, other endo-
crine disorders or syndromic features were not reported
in any of these patients. Ethical review board approval
wasgrantedandinformedconsentwasobtainedfromall
parents according to institutional guidelines.
Molecular analysis of NR5A1
Genomic DNA was extracted from peripheral blood
leukocytes using a Qiamp DNA blood kit (Qiagen).
Direct sequencing of the six coding exons of NR5A1
(exons 2–7) was performed as described previously (18).
Splice-site mutation
Genscan splice prediction software (http://genes.mit.
edu/GENSCAN.html) was used to assess the conse-
quences of the splice site mutation detected.
Transient gene expression assays
Expression vectors containing the p.E11X or p.Q107X
nonsense mutants were generated by site-directed
mutagenesis (QuikChange, Stratagene, Amsterdam,
The Netherlands) using wild-type (WT) pCMXSF-1 as
a template. The entire coding sequence was conﬁrmed
by direct sequencing prior to functional analyses.
Transient transfection studies were performed in
96-well plates using lipofectamine 2000 (Invitrogen)
and a dual-luciferase reporter assay system (Promega).
Studies were performed in tsa201 human embryonic
kidney cells by transfecting empty, WT, or mutant SF-1
expression vectors (2 ng/well; p.G35E, p.E11X,
p.Q107X,) with the SF-1-responsive minimal promoter
of Cyp11a linked to luciferase (100 ng/well). Cells were
lysed 24 h following transfection and assayed for
luciferase activity (Dual Luciferase Reporter Assay
system, Promega; FLUOstar Optima, BMG Labtech,
Aylesbury, UK), with standardization for Renilla
co-expression. Results are shown as the meanGS.E.M.
of three independent experiments, each performed
in triplicate.
Studies of SF-1 nuclear localization
Mutant GFP-SF-1 constructs were generated by site-
directed mutagenesis in a pAcGFP-C1 vector (Clontech)
to produce mutant fusion proteins with a GFP tag at the
amino-terminus of SF-1. WT and mutant pAcGFP-
C1SF-1 expression vectors (0.8 mg) were transfected
intotsa201cells.After24 h,cellswereﬁxedandnuclear
counterstaining performed with Vectashield containing
DAPI (Vector Laboratories, Peterborough, UK) (data not
shown).
Results
Cohort analysis
SF-1 (NR5A1) mutations were found in 3 out of
60 (5%) patients studied. An overview of these
changes and clinical phenotypes is provided in
Table 1. Of note, these changes were found only in
patients with severe penoscrotal hypospadias and
undescended testes (3 out of 20, 15%). No SF-1
mutations were found in this cohort in those patients
with penile hypospadias and/or bilaterally descended
testes.
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All three patients were diagnosed with severe hypos-
padias and undescended inguinal testes at birth.
Subject 1 had a normal penile length at birth whereas
subjects 2 and 3 both had a small phallus (subject 2,
2.5 cm, K2.5 SDS at birth; subject 3, 2 cm, K3.8 SDS
at 4 years; Table 1). Only patient 2 displayed a minimal
chordee. In all the cases, there was a single opening at
the base of phallus with no vaginal introitus. Complete
scrotal midline fusion was seen in all patients, although
the scrotum was slightly hypoplastic with decreased
plication in patients 2 and 3. Endocrine evaluation at
diagnosis showed low basal testosterone levels in all
three patients and impaired testosterone response to
human chorionic gonadotrophin (hCG) stimulation
when tested (patients 2 and 3). Furthermore, patient
1 had low anti-Mu ¨llerian hormone (AMH) levels at 4
years of age and patient 2 had low inhibin B and
slightly elevated FSH at 7 days of age (Table 1). No
Mu ¨llerian structures were found by ultrasound in
patients 1 and 3, whereas a uterine remnant was
suspected by ultrasound in patient 2, which was
revealed to be a vaginal rest by genitography and
laparoscopy. Bilateral inguinal gonads consistent with
the testes were seen by ultrasound in all three patients
(patient 1, 2 ml/2 ml at 4 years; patient 2, 1 ml/1 ml at
birth; patient 3, 3 ml/3 ml at 4 years). As testicular
architecture appeared normal, no biopsies were
performed. Male gender assignment was made in
subjects 1 and 2 at birth and hypospadias repair and
orchidopexy was undertaken. Patient 3 was born in a
rural area of Egypt and presented to the National
Research Center of Cairo at the age of 4 years. At that
time, a small phallus (2 cm), penoscrotal hypospadias
and inguinal testes were seen. The karyotype was
46,XY, testosterone was low before and after hCG
stimulation, and no uterus was present (Table 1). Until
this point the patient had been raised as a girl but
gender reassignment was considered based on the
clinical features, investigations, and parental views. A
trial of DHT cream (Andractim 2.5%, applied to the
phallus once daily at a dose of w5–10 mg daily)
resulted in an increase in phallic length from 2 to
2.5 cm and gender reassigment to male is currently in
progress. Of note, basal cortisol, 17-hydroxyprogester-
one and DHEAS were within normal ranges in patient
1 and 2 at diagnosis, and no symptoms or signs of
adrenal insufﬁciency have emerged in any of the
patients during follow up.
SF-1 (NR5A1) mutations detected
Patient 1 has a heterozygous C to T substitution in
exon 4 (c.319 COT) resulting in a change from
glutamine to a stop codon at position 107 (p.Q107X/
WT) (Fig. 1A). Patient 2 has a heterozygous C to A
substitution within the splice acceptor site of intron
2 (c.103-3COA/WT; ctcccgcagGGCTTCOctcccgaag
GGCTTC). Patient 3 has a heterozygous G to T
substitution in exon 2 (c.31GOT) resulting in a change
from glutamate to a stop codon at position 11
(p.E11X/WT). Analysis of DNA from 100 healthy
control subjects (200 alleles) did not detect any of
these novel changes by restriction analysis.
Table 1 Clinical, biochemical, and genetic characteristics of the three patients with NR5A1 mutations in this series.
Patient Age
External
genitalia Testes
a Uterus
a
Endocrine data at
diagnosis
Sex
assignment Mutation
1 At birth Normal phallus; peno-
scrotal hypospadias;
bilateral inguinal
gonads
Yes No Age 7 days: testosterone
0.4 ng/ml LH 1.2 U/l,
FSH !1 U/l
_ p.Q107X/WT
(exon 4)
Age 4 years: inhibin B
63 pg/ml AMH 15 ng/ml
(low)
2 At birth Phallus 2.5 cm
(K2.5 S.D.) with
minimal chordee; scro-
tal hypospadias;
bilateral inguinal
gonads
Yes No
(vaginal rest)
Age 7 days: hCG stimu-
lation: testosterone
0.4/0.9 ng/ml LH
0.65 U/l, FSH 7.9 U/l
Inhibin B 47 pg/ml (low)
_ c.103-3CO
A/WT (intron
2 splice
acceptor
site)
3 4 years Phallus 2 cm (K3.8 S.D.);
(2.5 cm after DHT);
penoscrotal hypospa-
dias; bilateral inguinal
gonads
Yes No Age 4 years: hCG stimu-
lation: testosterone
0.05/0.58 ng/ml
\O_ p.E11X/WT
(exon 2)
Normal range of: basal testosterone at 7 days 0.12–2.0 ng/ml, 6 months to 7 years !0.1–0.65 ng/ml; LH at 7 days 0.1–1.0 U/l; FSH at 7 days 0.3–4.0 U/l;
inhibin B at 0–1 months 68–630 pg/ml, 4–10 years 50–258 pg/ml; anti-Mu ¨llerian hormone at 4 years 45–85 ng/ml (conversion factors to SI units are: 3.47 for
testosterone (nmol/l), 7.14 for AMH (pmol/l)). Cortisol, DHEAS, and 17-hydroxyprogesterone as markers of basal adrenal function were all normal where
studied.
aTestes/uterus as visualized by ultrasound and/or laparoscopy (patient 2).
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p.Q107X)
The two nonsense mutants studied (p.E11X, p.Q107X)
showed markedly impaired transcriptional activity in an
established assay of SF-1 function (Fig. 1B). Although
these changes might be subject to nonsense mediated-
decay, any translated p.E11X or p.Q107X protein would
be predicted to lack of most of the functional domains
of SF-1 (Fig. 1A) and have altered nuclear localization
(Fig. 1C).
Altered splicing (c.103-3COA)
Using Genscan splice prediction software, the c.103-
3COA change is likely to affect splicing at the intron
2–exon 3 splice acceptor site. Potentially, an additional
three amino acids (LPK) are inserted into the ﬁrst zinc
ﬁnger of the SF-1 protein. This insertion between
codons 34 and 35 would disrupt the proximal (‘P’)
box motif (ESCKGOESCKLPKG), the critical DNA
binding region of SF-1.
Discussion
Steroidogenic factor 1 (NR5A1) is a transcription factor
that plays a central role in gonadal and adrenal
development. SF-1 also regulates the transcription of
several enzymes involved in steroid/androgen biosyn-
thesis. Although the initial search for SF-1 changes in
humans focused on patients with combined gonadal
and adrenal failure (19, 20), more recent case reports
and series have shown that heterozygous NR5A1 (SF-1)
mutations can be found relatively frequently in 46,XY
patients with severe underandrogenization, mild or
partial gonadal dysgenesis, impaired androgen
synthesis, and apparently normal adrenal function,
or in 46,XX girls or women with ovarian insufﬁciency
(17, 18, 21–26). Thus, patients with SF1 mutations can
present with a predominantly gonadal phenotype
in humans (27). So far, most of the reported patients
with severe underandrogenization have been raised
as females.
A spectrum of phenotypes exists for most develop-
mental endocrine conditions. As we have reported a
SF-1 mutation (p.L437Q) in one patient (penoscrotal
hypospadias, high scrotal testes) who was raised male,
we hypothesized that loss-of-function mutations in SF-1
might also be found in 46,XYpatients with hypospadias
but without adrenal failure (17). Indeed, a milder loss of
function change in SF-1 has been reported in
association with micropenis and bilateral anorchia,
and a nonsynonymous polymorphism in SF-1 may be
associated with micropenis and undescended testes in
population studies (28–30).
In the cohort of children with a range of nonsyn-
dromic hypospadiac disorders described here, novel
heterozygous SF-1 (NR5A1) mutations were found in
5% (3/60) of the entire group, and in 3/20 (15%) of
those with the most severe phenotype comprising severe
penoscrotal hypospadias, small to normal phallus,
inguinal testes and low testosterone levels. In patient 2
gonadal dysgenesis was present at birth as reﬂected by
the low inhibin B, AMH and testosterone levels and the
presence of a vaginal rest as a rudimentary Mu ¨llerian
structure. In patient 1, the decreased testosterone level
at birth and the lowamount of inhibin B in infancy may
represent progressive gonadal dysgenesis. Patient 1 and
2 were raised as males from birth, whereas gender
assignment in patient 3 was more challenging on
accountofadelayedpresentationandthegreaterdegree
of genital ambiguity. Taken together, these cases show
that heterozygous loss-of-function mutations in SF-1
(NR5A1) can be found in children with severe forms of
hypospadiasandthatmalesexofrearingofchildrenwith
SF-1 mutations is possible, but SF-1 mutations are not
Figure1 (A) Cartoonofthe structureofSF-1showingthe positionof
the nonsense mutations reported here (p.E11X, p.Q107X) together
with that of the previously reported p.Y138X change (18). (B) The
p.E11X and p.Q107X mutants show impaired transcriptional activity
in an assay using the minimal promoter of Cyp11a in tsa201 cells.
The activity of the previously described p.G35E mutant is shown for
comparison (19). Data represent the meanGS.E.M. of three
independent experiments, each performed in triplicate. (K), empty
vector; WT, wild-type; RLU, relative lights units. (C) Expression and
cellular localization of WT and mutant GFP-SF-1 fusion proteins.
WT GFP-SF-1 localizes in the nucleus with relative nucleolar
exclusion. A truncated protein corresponding to the p.E11X
nonsense mutant reported here is located throughout the cell, whilst
low levels of cytoplasmic fusion protein are seen with p.Q107X. In
contrast, the previously reported p.Y138X change is strongly
localized to the nucleus with signal in the nucleolus too (18). These
studies largely support reports that the nuclear localization signal of
SF-1 requires codons 89–101 with bipartite basic motifs at either
end of this region being particularly important (33).
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hypospadias. To date, none of these patients have shown
evidence of adrenal insufﬁciency, and it is uncertain if
patients with SF-1 mutations are at risk of developing
adrenal insufﬁciency in later life. Two patients with
46,XY DSD and adrenal failure have been reported,
which may reﬂect more signiﬁcant loss of SF-1 function
inthesecases(19,20,31).Furthermore,itisunknownif
DSD or hypospadiac patients with SF-1 mutations will
have normal puberty and fertility or if there is an
increased risk of testicular tumors due to gonadal
dysgenesis. Subsequently, individuals with SF-1
mutations need long-term follow-up of adrenal and
hypothalamic–pituitary–gonadal function and regular
screening for gonadal tumors. In some individuals, sex
assignment is challenging and long-term studies of
gender identity and psychosexual functioning are
needed. Thus, deﬁning NR5A1 (SF-1) mutations of this
group of individuals with severe hypospadias may have
important implications in their later life, although
further research is needed before speciﬁc guidelines or
recommendations for genetic screening can be made.
In addition to the clinical implications of these
ﬁndings, the identiﬁcation of these three novel NR5A1
changes provides some insight into the biological
function of SF-1. RNA containing the c.31GOT
(p.E11X) or c.319 COT (p.Q107X) changes may be
subject to nonsense mediated decayas well as loss of key
functional domains in any translated protein (32).
However, these naturally occurring changes, taken
together with the previously reported p.Y138X
mutation, support the hypothesis that the nuclear
localization signal of SF-1 requires integrity of a
bipartite basic motif around codons 89–101 in the
distal DNA-binding and proximal hinge regions
(Fig. 1C) (18, 33). Thus, the p.E11X mutant protein is
located throughout the cell, whereas the p.Q107X
protein is largely nuclear and the p.Y138X protein
exclusively so. In contrast, the c.103-3COA splice
acceptor site change is predicted to generate a novel
translated protein with insertion of three amino acids
into the P-box (proximal) of the DNA-binding domain.
This P-box motif is crucial for major groove binding and
for dictating target gene speciﬁcity by nuclear receptors
(34). However, the effects of splice site changes are often
not complete and some normal protein is produced,
which may contribute to the milder phenotype seen in
this patient compared with the previously described
individual with a p.G35E missense mutation in the
P-box motif (19). It is also likely that modiﬁer genes or
epigenetic or environmental factors can inﬂuence
individual phenotypes on top of a background of SF-1
haploinsufﬁciency.
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